ClinicalTrials.gg

TargetBeta

SLC6A3

solute carrier family 6 member 3 · also DAT, DAT1 · Solute carrier family 6

4 programs in company-led studies act on SLC6A3, from 4 companies: 0 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
BupropionruleGlaxoSmithKlinephase 4291 runningSLC6A2ChEMBL
lisdexamfetamineruleTakedaphase 4470 runningSLC18A2, SLC6A2ChEMBL
dexmethylphenidateruleCingulate Therapeuticsphase 4140 runningSLC6A2ChEMBL
AmphetamineruleTris Pharmaphase 480 runningSLC6A2ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.